August 2023
1. SHAH P, Jacobson C
   Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.
   Hematol Oncol Clin North Am. 2023 Aug 31:S0889-8588(23)00104.
   

   >> Share

   
   July 2023
2. MCCLORY SE, Maude SL
   The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia.
   Hematol Oncol Clin North Am. 2023 Jul 25:S0889-8588(23)00091.
   

   >> Share

   
   
3. CUMMINS K, Gill S
   Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
   Hematol Oncol Clin North Am. 2023 Jul 11:S0889-8588(23)00092.
   

   >> Share

   
   February 2022
4. MELLINGHOFF IK, Chang SM, Jaeckle KA, van den Bent M, et al
   Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.
   Hematol Oncol Clin North Am. 2022;36:95-111.
   

   >> Share

   
   August 2021
5. BROWN JR
   Chronic Lymphocytic Leukemia: So Much Progress, Still Challenges Ahead.
   Hematol Oncol Clin North Am. 2021;35:xiii-xiv.
   

   >> Share

   
   
6. SHADMAN M, Maloney DG
   Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
   Hematol Oncol Clin North Am. 2021;35:847-862.
   

   >> Share

   
   
7. SUN C, Wiestner A
   Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
   Hematol Oncol Clin North Am. 2021;35:827-845.
   

   >> Share

   
   
8. LAMPSON BL, Brown JR
   The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
   Hematol Oncol Clin North Am. 2021;35:807-826.
   

   >> Share

   
   
9. THOMPSON MC, Mato AR
   Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
   Hematol Oncol Clin North Am. 2021;35:793-806.
   

   >> Share

   
   
10. LASICA M, Tam CS
    Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
    Hematol Oncol Clin North Am. 2021;35:761-773.
    

    >> Share

    
    
11. DING W
    The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
    Hematol Oncol Clin North Am. 2021;35:739-759.
    

    >> Share

    
    
12. CHERNG HJ, Jain N
    First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
    Hematol Oncol Clin North Am. 2021;35:725-738.
    

    >> Share

    
    
13. VLACHONIKOLA E, Sofou E, Chatzidimitriou A, Stamatopoulos K, et al
    The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications.
    Hematol Oncol Clin North Am. 2021;35:687-702.
    

    >> Share

    
    
14. NG A, Chiorazzi N
    Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:665-685.
    

    >> Share

    
    
15. THANGAVADIVEL S, Woyach JA
    Genomics of Resistance to Targeted Therapies.
    Hematol Oncol Clin North Am. 2021;35:715-724.
    

    >> Share

    
    
16. LJUNGSTROM V, Baliakas P
    Prognostic and Predictive Implications of Cytogenetics and Genomics.
    Hematol Oncol Clin North Am. 2021;35:703-713.
    

    >> Share

    
    May 2021
17. AL-SAWAF O, Seymour JF, Kater AP, Fischer K, et al
    Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Hematol Oncol Clin North Am. 2021 May 15. pii: S0889-8588(21)00039.
    

    >> Share

    
    April 2021
18. JAIN T, Rampal RK
    Accelerated and Blast Phase Myeloproliferative Neoplasms.
    Hematol Oncol Clin North Am. 2021;35:325-335.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share